Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
Rockwell Medical RMTI delivered an impressive performance through 2024, with its stock witnessing more than 108% year-to-date surge, outperforming the 15.5% rise of the industry and the benchmark’s 18.1% increase.
The company also strongly outperformed its key rivals like EDAP TMS EDAP and IRIDEX IRIX year to date. EDAP TMS has fallen 40.3% and IRIDEX has declined 32.3% during this period.
YTD Share Comparison
This year can be regarded as a momentous period for Rockwell Medical’s business because this is the first time in the company’s history that it has achieved a steady revenue growth path, with a projection of more than $100 million in annual sales. Further, in 2024 so far, the company has reported an improving trend of gross profit, improved gross margin (from a negative number to a consistently growing positive number), attained sustained profitability, and, last but not least, significantly lowered its debt burden.
As of the latest trading session, the stock closed at $3.94, a little below its 52-week high of $4.38.
RMTI Stock Above SMAs
RMTI stock is also trading significantly above both its 50-day and 200-day moving averages since Aug. 8, 2024. The stock is also enjoying a golden crossover support as its 50-day moving average has been consistently ahead of the 200-day moving average since June 28. This, while indicating the possibility of a further bullish shift in the stock's price, is generating strong optimism among investors.
RMTI Stock Above 50 & 200-Day SMA & a Golden Crossover
Major Factors Driving RMTI Shares
High Growth Markets: Going by a recent Grand View Research report, the U.S. hemodialysis and peritoneal dialysis market size was valued at $36.21 billion in 2022 and is projected to expand at a CAGR of 6.10% from 2023 to 2030.Last year, following RMTI’s acquisition of the hemodialysis concentrates business from Evoqua, the number 3 player in the hemodialysis market at that time, the market has now consolidated to two primary players who cater to the over 12,000 dialysis clinics in the United States. Considering the rising incidence of Acute Kidney cases and risks associated with transplants, the expansion in the field of hemodialysis concentrates has opened up enormous prospects for the company in this space. With the latest consolidation, Rockwell Medical has now been acknowledged as the only independent supplier of concentrates with the scale and distribution to service these in-center and hospital-based clinics.
Running a Successful Revenue Model: Rockwell Medical has started to accurately price its products in the hemodialysis market. At the beginning of 2024, the company undertook a new program to adjust its product pricing structure to reflect the inherent value its products bring to providers. In the second quarter of 2024, the company generated net sales of $25.8 million, which was largely driven by improved value-based pricing and increasing volumes. Annualizing the second-quarter 2024 net sales would put RMTI north of $100 million in revenues, a goal that the company set out to achieve two years back.
Margin Efficiencies: Gross margin continues to trend upward in 2024 as Rockwell Medical further optimizes its business through improved processes, automated manufacturing and enhanced distribution capabilities through the modernization of the company’s infrastructure and technology solutions. Through the first two quarters of 2024, RMTI achieved consecutive quarters of improved gross profit and gross margin. The company reported 18% gross margin for the second quarter, exceeding the company’s gross margin guidance of 18% for the full year of 2024.
Generating Positive Cash Balance: The combination of increased sales and greater gross margin has led to cash flow from operations of $1.4 million for the second quarter of 2024 and, as a consequence, an increase in RMTI’s cash balance. The company’s cash balance has gone from $8.6 million at the end of the first quarter to $11.9 million at the end of the second quarter. For the first time in recent history, RMTI achieved profitability on a cash flow and adjusted EBITDA basis in the second quarter of 2024. The company considers this a turning point and expects to build upon this momentum in the coming quarters.
Bullish Projections for 2025: For 2025 and beyond, Rockwell Medical is focused on two areas. First, it intends to grow the company’s concentrates business and make it more profitable as the company continues to work toward keeping annual revenues above $100 million and gross margins up to 30%. Second, it intends to expand beyond concentrates.
Upward Estimate Revisions for RMTI
The Zacks Consensus Estimate for RMTI’s 2024 earnings has been revised upward over the past 60 days. It has been narrowed to a loss of 3 cents from a loss of 14 cents over this period.
RMTI Trading Cheap
This is evident from the price/sales ratio. RMTI shares currently trade at 1.17X forward earnings, well off its five-year high of 2.73X but ahead of its median of 0.56X. The stock is also trading significantly below the industry’s price/sales ratio of 5.80.
Final Take on RMTI
Rockwell Medical continues to outperform its peers in a challenging market for medical devices, banking on its continued efforts to focus on optimizing business to drive sustainable profitability and meaningful cash flow generation. The company is working on enhancing cash balance through the profits generated in the business and is beginning to reinvest those profits back into the business. RMTI also continues to reduce the cost of manufacturing products by adding new equipment and enhancing its infrastructure to fully automate its processes.
While other industry peers face uncertainty due to supply issues and other macroeconomic headwinds, the company’s growth strategies position it for continued success over the upcoming period. Although the high-interest rate environment remains a concern for investors, upward revisions in earnings estimates reinforce RMTI’s Zacks Rank #1 (Strong Buy). This makes RMTI worthy of addition to investors' portfolios at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks Investment Research
European equities traded in the US as American depositary receipts were trending modestly lower late Tuesday morning, declining 0.16% to 1,445.76 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company Genfit and pharmaceutical company Ascendis Pharma , which rose 6.8% and 5.7% respectively. They were followed by internet advertising firm Criteo and biotech firm BioNTech , which increased 2.3% and 0.5% respectively.
The decliners from continental Europe were led by furniture maker Natuzzi and medical device maker EDAP TMS , which fell 6.7% and 3.3% respectively. They were followed by biotech firm Evaxion Biotech and biopharmaceutical company DBV Technologies , which lost 2.8% and 1.5% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals and Akari Therapeutics , which were up 2% and 3.6% respectively. They were followed by pharmaceutical company Silence Therapeutics and insurance company Prudential , which increased 3.4% and 1.3% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana , which tumbled 31.4%, followed by tobacco company British American Tobacco , which was down 2.7%. Pharmaceutical company GSK and medical device maker Smith & Nephew dropped 1.7% and 1.2% respectively.
European equities traded in the US as American depositary receipts started the week higher late Monday morning, rising 0.31% to 1,446.05 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by pharmaceutical company Ascendis Pharma and biotech firm Evaxion Biotech , which advanced 19% and 6.7% respectively. They were followed by biopharmaceutical company Genfit and 3D printer company Materialise , which were up 5.2% and 5% respectively.
The decliners from continental Europe were led by furniture maker Natuzzi and medical device maker EDAP TMS , which fell 4% and 3.7% respectively. They were followed by biopharmaceutical companies Cellectis and Grifols , which declined 2.6% and 1.7% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical firm NuCana , which soared 150%, followed by TC Biopharm and Trinity Biotech , which were up 5.3% and 1.9%, respectively.
The decliners from the UK and Ireland were led by Bicycle Therapeutics and Biodexa Pharmaceuticals , which lost 7.5% and 4.4% respectively. They were followed by Adaptimmune Therapeutics , which was down 4.2%.
European equities traded in the US as American depositary receipts were moving lower late Wednesday morning as the S&P Europe Select ADR Index was down 0.31% to 1,406.11.
From continental Europe, the gainers were led by biopharmaceutical companies Grifols and Cellectis , which rose 5% and 3%, respectively. They were followed by biotech firm Evaxion Biotech and biopharmaceutical company Genfit , which were up 2.8% and 2%, respectively.
The decliners from continental Europe were led by furniture maker Natuzzi and biopharmaceutical company DBV Technologies , which dropped 5.7% and 3.8%, respectively. They were followed by medical device maker EDAP TMS and telecommunications company Ericsson , which fell 2.8% and 2.1%, respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Verona Pharma , which increased 3.2%, followed by biopharmaceutical company Bicycle Therapeutics and telecommunications operator Vodafone Group , which rose 0.8% each, while biopharmaceutical company Akari Therapeutics was up 0.6%.
The decliners from the UK and Ireland were led by biopharmaceutical companies TC Biopharm and Biodexa Pharmaceuticals , which lost 8.9% and 5.7%, respectively. They were followed by biopharmaceutical companies NuCana and Amarin , which were down 5.4% and 3.9%, respectively.
European equities traded in the US as American depositary receipts were moving sharply lower late Tuesday morning, falling 1.21% to 1,404.91 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies and biotech firm BioNTech , which rose 2.6% and 2.3%, respectively. They were followed by semiconductor company Sequans Communications and furniture maker Natuzzi , which were down 1.5% and 1.4%, respectively.
The decliners from continental Europe were led by telecommunications company VEON and medical device maker EDAP TMS , which retreated 6.9% and 3.5%, respectively. Biopharmaceutical firm Grifols lost 3.3% and financial services company Banco Santander was down 2.8%.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics and TC Biopharm , which advanced 8.5% and 3.9%, respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Mereo BioPharma Group (MREO), which rose 3.6% and 2.3%, respectively.
The decliners from the UK and Ireland were led by financial services companies Barclays and Lloyds Banking Group , which fell 3% and 2.8%, respectively. Biopharmceutical company NuCana was down 2.6% and financial services company HSBC lost 2.3%.
Sept 9 (Reuters) - Rockwell Medical Inc RMTI.O:
ROCKWELL MEDICAL ANNOUNCES PRODUCT PURCHASE AGREEMENT WITH LEADING AT-HOME AND ACUTE CARE DIALYSIS PROVIDER
Source text for Eikon: (Full Story)
Further company coverage: RMTI.O
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.